20. November 2009 11:24
The debate on how to select patients who will respond best to costly drug treatments for aggressive breast cancer now favors fluorescence in situ hybridization (FISH) to measure the HER-2 receptor found in human breast tumors, according to a leading pathologist presenting at the Association for Molecular Pathology annual meeting.
[More]
cb589363-95d8-48b5-b93d-447399d1a7e5|0|.0
Posted in: Device / Technology News | Women's Health News
Tags: Adjuvant Therapy, Breast Cancer, Cancer, Chemotherapy, Cyclophosphamide, DNA, Doxorubicin, Fluorouracil, Mammography, Oncology, Pathology
20. November 2009 09:28
Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer).
[More]
9de2aaf9-d1dc-42a8-8d75-d56e72072c7e|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Biotechnology, Cancer, Cell, Chemotherapy, Glioma, Kidney Cancer, Lymphoma, Melanoma, Oncology, Renal Cell Carcinoma, Vaccine
20. November 2009 09:14
Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex® Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.
[More]
20. November 2009 09:02
Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.
[More]
4860eda6-fe31-4d8b-a8a6-7cc875daf80d|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abraxane, Apoptosis, Bone, Cancer, Cell, Chemotherapy, Dacarbazine, DNA, Docetaxel, Evolution, Melanoma, Neutropenia, Oncology, Paclitaxel, Skin Cancer, Temozolomide
20. November 2009 01:37
Research and Markets (http://www.researchandmarkets.com/research/4b82d8/cancer_therapies) has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering.
[More]
d1ec933e-6b16-4c92-bf1f-1cae23f4af72|0|.0
Posted in: Device / Technology News
Tags: Abraxane, Antibody, Avastin, Bone, Bone Marrow, Cancer, Cell, Chemotherapy, Colorectal Cancer, Diabetes, Drug Delivery, Gemzar, Genetics, Genomics, Hormonal Therapy, Immunization, Immunotherapy, Pfizer, Proteomics, Radiation Therapy, Smoking, Stem Cell, Tarceva, Taxotere, Xeloda
19. November 2009 10:37
Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
[More]
0f477df3-7276-483a-9f16-5c5e959136a1|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antisense, Apoptosis, Biotechnology, Cancer, Cell, Chemotherapy, Hepatocellular Carcinoma, Leukemia, Lymphoma, Oncology, Sorafenib
19. November 2009 09:35
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
[More]
19. November 2009 05:54
"The recommendation to change breast screening is a huge step backwards," says Dr. Marisa Weiss, a leading breast oncologist and founder and president of Breastcancer.org.
[More]
19. November 2009 05:00
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it has won first prize in Deloitte's Technology Fast 50 2009TM ranking of France's fastest-growth technology companies.
[More]
19. November 2009 04:58
The United States Preventive Services Task Force has announced new guidelines for when a woman should be getting a mammography. The Maurer Foundation's Founder, Breast Surgeon Dr. Virginia Maurer, has made an official statement regarding her research and beliefs on the subject.
[More]
19. November 2009 03:13
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
[More]
7169822c-90e7-4db1-bb27-26e0162bbe54|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cancer, Cell, Chemotherapy, Chronic Lymphocytic Leukemia, Cough, Cyclophosphamide, Headache, Hepatitis B, Leukemia, Lymphoma, MabThera, Methotrexate, Multiple Sclerosis, Nausea, Rheumatoid Arthritis, Rituximab, Virus
19. November 2009 02:25
Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects.
[More]
19. November 2009 01:34
A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six weeks, has arrived at Cancer Treatment Centers of America(R) (CTCA) in Philadelphia. CTCA will become the first in the country to offer this treatment option using the Novac7 technology from Rome, Italy.
[More]
19. November 2009 00:22
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
[More]
9f19f465-9b09-4558-8717-5dc5f9c0f5b8|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Anorexia, Biopsy, Biotechnology, Cancer, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diarrhea, Erlotinib, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Pfizer, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting
18. November 2009 23:55
BSD Medical Corporation (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.
[More] 
Subscribe